Compound: deferiprone
SMILES: O=c1c(O)c(n(C)cc1)C
InChIKey: TZXKOCQBRNJULO-UHFFFAOYSA-N
Synonyms: deferiprone, 30652-11-0, 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone, Ferriprox, 3-hydroxy-1,2-dimethylpyridin-4(1H)-one, CP20, 1,2-Dimethyl-3-hydroxypyrid-4-one, 4(1H)-Pyridinone, 3-hydroxy-1,2-dimethyl-, 3-hydroxy-1,2-dimethylpyridin-4-one, APO-66, Deferiprona, Deferipron, APO-066, DN-180-01-AF, 1,2-Dimethyl-3-hydroxy-4(1H)-pyridinone, DTXSID6040666, CP-20, DN-18001AF, 2BTY8KH53L, NSC-758880, CHEBI:68554, 4(1H)-Pyridinone, 1,2-dimethyl-3-hydroxy-, 1,2-dimethyl-3-hydroxy-4-pyridinone, 3-Hydroxy-1,2-dimethyl-4-pyridinone, 4(1H)-Pyridone, 3-hydroxy-1,2-dimethyl-, DTXCID4020666, DMOHPO, HDMPP, Deferipronum, 1,2 Dimethyl 3 hydroxypyrid 4 one, 1,2-dimethyl-3-hydroxypyridin-4-one, 1,2 Dimethyl 3 hydroxy 4 pyridinone, 1,2 Dimethyl 3 hydroxypyridin 4 one, 3 Hydroxy 1,2 dimethyl 4 pyridinone, RefChem:57612, V03AC02, 629-275-0, 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone, MFCD00134497, Deferiprone (INN), PL-1, L1, MLS000069481, 1,2-dimethyl-3-hydroxy-4-pyridone, HK-1, PL1, 3-hydroxy-1,2-dimethyl-pyridin-4-one, SMR000059136, DEFERIPRONE [INN], L-1, 1,2-Dimethyl-3-hydroxypyridine-4-one, CP20 (Chelating agent), Ferriprox (TN), 3-hydroxy-1,2-dimethylhydropyridin-4-one, UNII-2BTY8KH53L, BRN 1447108, Deferum, Deferiprone [USAN:INN:BAN], CCRIS 8318, Deferiprone CRS, Deferiprone (Standard), Opera_ID_366, DEFERIPRONE [MI], Deferiprone (USAN/INN), DEFERIPRONE [USAN], DEFERIPRONE [VANDF], DEFERIPRONE [MART.], SCHEMBL94474, DEFERIPRONE [WHO-DD], 3-hydroxy-1,2-dimethyl-1,4-dihydropyridin-4-one, MLS000758227, MLS001424029, MLS006011689, CHEMBL70927, DEFERIPRONE [EMA EPAR], CRMD-001, GTPL7456, orb1308158, HSDB 8335, HY-B0568R, TZXKOCQBRNJULO-UHFFFAOYSA-, DEFERIPRONE [ORANGE BOOK], EX-A972, CP020, DEFERIPRONE [EP MONOGRAPH], HMS2051C05, HMS2232E24, HMS3264P17, HMS3393C05, HMS3873L13, Pharmakon1600-01504512, HY-B0568, 3-hydroxy-1,2-dimethylpyrid-4-one, Tox21_112429, BBL036482, BDBM50525976, CGP-37391, EBC-04014, NSC758880, s4067, SBB006753, STL559018, 1,2-dimetyl-3-hydroxy-4-pyridinone, AKOS015902286, CCG-100760, CS-5240, DB08826, DS-5493, FD20884, NC00010, NSC 758880, 3-hydroxy-1,2-dimethyl-4- pyridinone, NCGC00090548-01, NCGC00090548-02, NCGC00090548-04, NCGC00090548-05, AC-33026, BP-12415, ST093416, SY052576, SBI-0207041.P001, CAS-30652-11-0, DB-047826, H0944, NS00005705, D07416, 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone, 98%, AB00572605_11, AB00572605_12, EN300-1718313, F239607, Q749664, SR-01000721891, 3-hydroxy-1,2-dimethylpyridin-4(1H)-one [M+H]+, Deferiprone 1,2-DIMETHYL-3-HYDROXY-4-PYRIDONE, SR-01000721891-4, BRD-K06878038-001-17-8, BRD-K06878038-001-18-6, Z1255390865, InChI=1/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3
Theoretical properties:
molecular_formula: C7H9NO2
molecular_weight: 139.15 g/mol
exact_mass: 139.063328530 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 0
heavy_atom_count: 10
topological_polar_surface_area: 40.5 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Needles from water
color: Needles from water
melting_point: 272-278
solubility: Maximum water solubility of 16–18 g/L at 24°
Descriptions:
pubchem: Deferiprone is a member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia. It has a role as an iron chelator and a protective agent.
chebi: A member of the class of 4-pyridones that is pyridin-4(1<em>H</em>)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
chembl: DEFERIPRONE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Deferiprone, sold under the brand name Ferriprox among others, is a medication that chelates iron and is used to treat iron overload in thalassaemia major.  It was first approved and indicated for use in treating thalassaemia major in 1994 and had been licensed for use in the European Union for many years while awaiting approval in Canada and in the United States. On 14 October 2011, it was approved for use in the US under the FDA's accelerated approval program.
The most common side effects include red-brown urine (showing that iron is being removed through the urine), nausea (feeling sick), abdominal pain (stomach ache) and vomiting. Less common but more serious side effects are agranulocytosis (very low levels of granulocytes, a type of white blood cell) and neutropenia (low levels of neutrophils, a type of white blood cell that fights infections).